Active — Not RecruitingNot Applicable

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Japan757 participantsStarted 2015-05-29

Plain-language summary

The purpose of this study is to investigate biomarkers which may be predictors of efficacy and safety of treatment with mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve unresectable advanced or recurrent colorectal cancer.

Who can participate

Age range20 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: (1) Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study Exclusion Criteria: (1) Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study

What they're measuring

Overall survival (OS)

Timeframe: Up to approximately 63 months

Trial details

NCT IDNCT02394834

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-09-30

View on ClinicalTrials.gov More Colorectal Cancer trials